Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.

Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M.

Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21.

PMID:
31227646
2.

Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer.

Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A, Santopaolo M, Votino C, Pancione M, Piepoli A, Mazzoccoli G, Binaschi M, Bigioni M, Maggi CA, Fassan M, Laudanna C, Matarese G, Sabatino L, Colantuoni V.

Cell Death Dis. 2016 Feb 25;7:e2120. doi: 10.1038/cddis.2016.28.

3.

Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 2: 7-fluorobenzothiophenes and benzofurans.

Marastoni E, Bartoli S, Berettoni M, Cipollone A, Ettorre A, Fincham CI, Mauro S, Paris M, Porcelloni M, Bigioni M, Binaschi M, Nardelli F, Parlani M, Maggi CA, Paoli P, Rossi P, Fattori D.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1603-6. doi: 10.1016/j.bmcl.2015.02.007. Epub 2015 Feb 24.

PMID:
25746815
4.

MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer.

Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente D, Forte N, Colantuoni V.

Neoplasia. 2013 Sep;15(9):1086-99.

5.

Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 1: hit identification.

Marastoni E, Bartoli S, Berettoni M, Cipollone A, Ettorre A, Fincham CI, Mauro S, Paris M, Porcelloni M, Bigioni M, Binaschi M, Nardelli F, Parlani M, Maggi CA, Fattori D.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4091-5. doi: 10.1016/j.bmcl.2013.05.053. Epub 2013 May 25.

PMID:
23768910
6.

Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures.

Bigioni M, Ettorre A, Felicetti P, Mauro S, Rossi C, Maggi CA, Marastoni E, Binaschi M, Parlani M, Fattori D.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5360-2. doi: 10.1016/j.bmcl.2012.07.067. Epub 2012 Jul 26.

PMID:
22877635
7.

SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.

Bellarosa D, Bressan A, Bigioni M, Parlani M, Maggi CA, Binaschi M.

Int J Oncol. 2012 Oct;41(4):1486-94. doi: 10.3892/ijo.2012.1551. Epub 2012 Jul 13.

PMID:
22797667
8.

Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety.

Animati F, Berettoni M, Bigioni M, Binaschi M, Cipollone A, Irrissuto C, Nardelli F, Olivieri L.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):5013-7. doi: 10.1016/j.bmcl.2012.06.016. Epub 2012 Jun 15.

PMID:
22749423
9.

Combined antihypertensive and cardioprotective effects of nebivolol and hydrochlorothiazide in spontaneous hypertensive rats.

Sacco G, Evangelista S, Manzini S, Parlani M, Bigioni M.

Future Cardiol. 2011 Nov;7(6):757-63. doi: 10.2217/fca.11.70.

PMID:
22050062
10.

4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.

Rossi C, Fincham CI, D'Andrea P, Porcelloni M, Ettorre A, Mauro S, Bigioni M, Binaschi M, Maggi CA, Nardelli F, Parlani M, Fattori D.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6767-9. doi: 10.1016/j.bmcl.2011.09.042. Epub 2011 Sep 18.

PMID:
21978679
11.

Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.

Rossi C, Porcelloni M, D'Andrea P, Fincham CI, Ettorre A, Mauro S, Squarcia A, Bigioni M, Parlani M, Nardelli F, Binaschi M, Maggi CA, Fattori D.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2305-8. doi: 10.1016/j.bmcl.2011.02.085. Epub 2011 Feb 26.

PMID:
21420859
12.

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

Binaschi M, Simonelli C, Goso C, Bigioni M, Maggi CA.

Exp Ther Med. 2011 Mar;2(2):173-180. Epub 2011 Jan 14.

13.

Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors.

Binaschi M, Boldetti A, Gianni M, Maggi CA, Gensini M, Bigioni M, Parlani M, Giolitti A, Fratelli M, Valli C, Terao M, Garattini E.

ACS Med Chem Lett. 2010 Jul 20;1(8):411-5. doi: 10.1021/ml1001163. eCollection 2010 Nov 11.

14.

Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA.

Bressan A, Bigioni M, Bellarosa D, Nardelli F, Irrissuto C, Maggi CA, Binaschi M.

Oncol Rep. 2010 Nov;24(5):1249-55.

PMID:
20878117
15.

Alpha-lipoic acid supplementation: a tool for obesity therapy?

Carbonelli MG, Di Renzo L, Bigioni M, Di Daniele N, De Lorenzo A, Fusco MA.

Curr Pharm Des. 2010;16(7):840-6.

PMID:
20388095
16.

The effects of Italian Mediterranean organic diet (IMOD) on health status.

De Lorenzo A, Noce A, Bigioni M, Calabrese V, Della Rocca DG, Di Daniele N, Tozzo C, Di Renzo L.

Curr Pharm Des. 2010;16(7):814-24.

PMID:
20388092
17.

Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.

Bigioni M, Parlani M, Bressan A, Bellarosa D, Rivoltini L, Animati F, Crea A, Bugianesi R, Maggi CA, Manzini S, Binaschi M.

Int J Cancer. 2009 Nov 15;125(10):2456-64. doi: 10.1002/ijc.24661.

18.

Role of interleukin-15 receptor alpha polymorphisms in normal weight obese syndrome.

Di Renzo L, Gloria-Bottini F, Saccucci P, Bigioni M, Abenavoli L, Gasbarrini G, De Lorenzo A.

Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):105-13.

PMID:
19309557
19.

Body composition and -174G/C interleukin-6 promoter gene polymorphism: association with progression of insulin resistance in normal weight obese syndrome.

Di Renzo L, Bertoli A, Bigioni M, Del Gobbo V, Premrov MG, Calabrese V, Di Daniele N, De Lorenzo A.

Curr Pharm Des. 2008;14(26):2699-706.

PMID:
18991689
20.

Sabarubicin (MEN10755)-induced apoptosis is independent from mtDNA in A2780 human ovarian tumor cells.

Bressan A, Nardelli F, Bellarosa D, Bigioni M, Curcurù G, Curatella B, Crea A, Maggi CA, Manzini S, Binaschi M.

Anticancer Res. 2007 Nov-Dec;27(6B):4039-46.

21.

Synthesis, biological evaluation, and molecular modeling studies of rebeccamycin analogues modified in the carbohydrate moiety.

Animati F, Berettoni M, Bigioni M, Binaschi M, Felicetti P, Gontrani L, Incani O, Madami A, Monteagudo E, Olivieri L, Resta S, Rossi C, Cipollone A.

ChemMedChem. 2008 Feb;3(2):266-79.

PMID:
18157856
22.

Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.

Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.

Cancer Chemother Pharmacol. 2008 Sep;62(4):621-9. Epub 2007 Nov 24.

PMID:
18038274
23.

Is antioxidant plasma status in humans a consequence of the antioxidant food content influence?

Di Renzo L, Di Pierro D, Bigioni M, Sodi V, Galvano F, Cianci R, La Fauci L, De Lorenzo A.

Eur Rev Med Pharmacol Sci. 2007 May-Jun;11(3):185-92.

PMID:
17970235
24.

Normal-weight obese syndrome: early inflammation?

De Lorenzo A, Del Gobbo V, Premrov MG, Bigioni M, Galvano F, Di Renzo L.

Am J Clin Nutr. 2007 Jan;85(1):40-5.

PMID:
17209175
25.

Interleukin-1 (IL-1) receptor antagonist gene polymorphism in normal weight obese syndrome: relationship to body composition and IL-1 alpha and beta plasma levels.

Di Renzo L, Bigioni M, Del Gobbo V, Premrov MG, Barbini U, Di Lorenzo N, De Lorenzo A.

Pharmacol Res. 2007 Feb;55(2):131-8. Epub 2006 Nov 19.

PMID:
17174563
26.

Normal Weight Obese syndrome: role of single nucleotide polymorphism of IL-1 5Ralpha and MTHFR 677C-->T genes in the relationship between body composition and resting metabolic rate.

Di Renzo L, Bigioni M, Bottini FG, Del Gobbo V, Premrov MG, Cianci R, De Lorenzo A.

Eur Rev Med Pharmacol Sci. 2006 Sep-Oct;10(5):235-45.

PMID:
17121316
27.

Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate.

Binaschi M, Parlani M, Bellarosa D, Bigioni M, Salvatore C, Palma C, Crea A, Maggi CA, Manzini S, Goso C.

Anticancer Drugs. 2006 Nov;17(10):1119-26.

PMID:
17075311
28.

Body composition analyses in normal weight obese women.

Di Renzo L, Del Gobbo V, Bigioni M, Premrov MG, Cianci R, De Lorenzo A.

Eur Rev Med Pharmacol Sci. 2006 Jul-Aug;10(4):191-6.

PMID:
16910350
29.

Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231.

Bigioni M, Benzo A, Irrissuto C, Maggi CA, Goso C.

Anticancer Drugs. 2005 Nov;16(10):1083-9.

PMID:
16222150
30.

Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.

Sacco G, Evangelista S, Criscuoli M, Goso C, Bigioni M, Binaschi M, Manzini S, Maggi CA.

Eur J Pharmacol. 2005 Mar 28;511(2-3):167-74.

PMID:
15792785
31.

MEN15658: a new promising anti-tumoral drug active on resistant tumor cells.

Salvatore C, Binaschi M, Bigioni M, Camarda G, Maggi CA, Goso C.

Anticancer Drugs. 2004 Feb;15(2):151-6.

PMID:
15075671
32.

CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival.

Palma C, Binaschi M, Bigioni M, Maggi CA, Goso C.

Int J Cancer. 2004 Jan 20;108(3):390-8.

33.

Pharmacological profile of MEN 11066, a novel potent and selective aromatase inhibitor.

Muratori M, Lippi A, Mancina R, Iafrate EM, Cirillo R, Lopez G, Bigioni M, Maggi M, Criscuoli M, Maggi CA.

J Steroid Biochem Mol Biol. 2003 Apr;84(5):503-12.

PMID:
12767275
34.

Anthracyclines: selected new developments.

Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, Animati F.

Curr Med Chem Anticancer Agents. 2001 Aug;1(2):113-30. Review.

PMID:
12678762
35.

Novel anthracycline oligosaccharides: influence of chemical modifications of the carbohydrate moiety on biological activity.

Cipollone A, Berettoni M, Bigioni M, Binaschi M, Cermele C, Monteagudo E, Olivieri L, Palomba D, Animati F, Goso C, Maggi CA.

Bioorg Med Chem. 2002 May;10(5):1459-70.

PMID:
11886808
36.

A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogue.

Bigioni M, Salvatore C, Bullo A, Bellarosa D, Iafrate E, Animati F, Capranico G, Goso C, Maggi CA, Pratesi G, Zunino F, Manzini S.

Biochem Pharmacol. 2001 Jul 1;62(1):63-70.

PMID:
11377397
37.

Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice.

Gonzalez-Paz O, Polizzi D, De Cesare M, Zunino F, Bigioni M, Maggi CA, Manzini S, Pratesi G.

Eur J Cancer. 2001 Feb;37(3):431-7.

PMID:
11239767
38.

Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat.

Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA.

Eur J Pharmacol. 2001 Feb 23;414(1):71-8.

PMID:
11230997
39.

Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides.

Arcamone F, Animati F, Bigioni M, Capranico G, Caserini C, Cipollone A, De Cesare M, Ettorre A, Guano F, Manzini S, Monteagudo E, Pratesi G, Salvatore C, Supino R, Zunino F.

Biochem Pharmacol. 1999 May 15;57(10):1133-9.

PMID:
11230800
40.

Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft.

Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S.

Br J Cancer. 2000 Jan;82(2):480-7.

41.

FCE 24517-resistant MCF-7 human breast cancer cell line: selection and characterization.

Salvatore C, Bigioni M, Iafrate EM, Cianfriglia M, Manzini S.

Anticancer Drugs. 1999 Aug;10(7):663-9.

PMID:
10507316
42.

Topoisomerase poisoning activity of novel disaccharide anthracyclines.

Guano F, Pourquier P, Tinelli S, Binaschi M, Bigioni M, Animati F, Manzini S, Zunino F, Kohlhagen G, Pommier Y, Capranico G.

Mol Pharmacol. 1999 Jul;56(1):77-84.

PMID:
10385686
43.

Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.

Pratesi G, De Cesare M, Caserini C, Perego P, Dal Bo L, Polizzi D, Supino R, Bigioni M, Manzini S, Iafrate E, Salvatore C, Casazza A, Arcamone F, Zunino F.

Clin Cancer Res. 1998 Nov;4(11):2833-9.

44.

Cytotoxic and antitumor activity of MEN 10710, a novel alkylating derivative of distamycin.

Bigioni M, Salvatore C, Palma C, Manzini S, Animati F, Lombardi P, Pratesi G, Supino R, Zunino F.

Anticancer Drugs. 1997 Oct;8(9):845-52.

PMID:
9402311
45.

Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo.

Arcamone F, Animati F, Berettoni M, Bigioni M, Capranico G, Casazza AM, Caserini C, Cipollone A, De Cesare M, Franciotti M, Lombardi P, Madami A, Manzini S, Monteagudo E, Polizzi D, Pratesi G, Righetti SC, Salvatore C, Supino R, Zunino F.

J Natl Cancer Inst. 1997 Aug 20;89(16):1217-23.

PMID:
9274917
46.

Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.

Animati F, Arcamone F, Bigioni M, Capranico G, Caserini C, De Cesare M, Lombardi P, Pratesi G, Salvatore C, Supino R, Zunino F.

Mol Pharmacol. 1996 Sep;50(3):603-9.

PMID:
8794900
47.

Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.

Bigioni M, Zunino F, Tinelli S, Austin CA, Willmore E, Capranico G.

Biochemistry. 1996 Jan 9;35(1):153-9.

PMID:
8555169
49.

Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II.

Capranico G, De Isabella P, Tinelli S, Bigioni M, Zunino F.

Biochemistry. 1993 Mar 30;32(12):3038-46.

PMID:
8384486
50.

Effect of X-rays on the differentiation of L5 myoblast cell line.

Scarpa S, Sapora O, Tabocchini MA, Di Renzo L, Bigioni M, Pazzaglia S, Palitti F, Carotti D, Strom R.

Ital J Biochem. 1989 Jul-Aug;38(4):263A-265A. No abstract available.

PMID:
2583975

Supplemental Content

Loading ...
Support Center